On April 1, the FDA added a video to its Patient Safety News page that discussed Chantix. The 2-1/2 minute clip was meant to update the public on Pfizer’s smoking-cessation pill, which had recently been the subject of a health advisory over neuropsychiatric side effects. But as WhyQuit pointed out, the video was taken down the next day.

We subsequently asked the FDA why this occurred and were told there was a technical issue and the content may require an upgrade, but the clip would be reposted shortly. That never happened. Meanwhile, the FDA talking head noted: “During the pre-market studies of this drug, people with serious psychiatric illnesses were not included and that means that the safety of the drug in these populations is really not known.”

Hat tip to Pharmagossip